Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news